BFBennett M. Ford

Bennett M. Ford

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bennett M. Ford has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The Endotheliopathy of Trauma Patients with Plasma Product Transfusion: Emerging Clinical Developments

    by Kalob M. Broocks, Bennett M. Ford, Shahab Ahmadzadeh, Sahar Shekoohi, Alan D. Kaye

  • Clinical Efficacy of Magnesium in Perioperative Pain Management: A Narrative Review

    by Shahab Ahmadzadeh, Joseph G. Wentling, Bennett M. Ford, Jade Alexandra Tom Yew, Sonnah A. Barrie, Faline Y. Bernhardt, Sahar Shekoohi, Alaa Abd-Elsayed, Alan D. Kaye

    Purpose of review Postoperative pain is a prevalent clinical challenge that often leads to high opioid consumption, delayed hospital discharge, and associated side effects. Inadequate pain control can delay recovery and contribute to the risk of chronic postsurgical pain and opioid dependence. Magnesium, an essential cation with diverse physiological roles, has gained attention as a non-opioid adjunct for perioperative analgesia related to multimodal mechanisms of action and a favorable profile. Recent findings Pharmacologically, magnesium acts as an N–methyl-D–aspartate (NMDA) receptor antagonist and calcium channel blocker in the central nervous system, dampening excitatory neurotransmission and reducing central sensitization to pain. It also exhibits anti-inflammatory and anti-nociceptive effects and is inexpensive and easy to administer intravenously. These properties make magnesium a cost-effective and simple addition to multimodal pain management protocols. When used as a preoperative or intraoperative adjunct, magnesium has demonstrated reduced postoperative pain intensity and decreased opioid requirements across various surgical populations. Trials and meta-analyses report that patients receiving perioperative magnesium experience lower pain scores and need fewer opioids in the first 24–48 hours after surgery, translating into an opioid-sparing effect and potentially less opioid-related nausea and sedation. Importantly, magnesium has a favorable safety profile at recommended doses and generally is well-tolerated with minimal side effects apart from infrequent hypotension or mild sedation. No significant respiratory depression occurs in patients with normal renal function. Summary The present investigation highlights magnesium-mediated analgesic mechanisms, summarizes clinical evidence for efficacy as a preoperative pain adjunct, and describes implications for improving postoperative pain outcomes and reducing opioid reliance in perioperative care.


  • Open Access

    Emerging Clinical Role of Tavapadon, a Novel Dopamine Partial Agonist, in the Treatment of Parkinson’s Disease

    by Alan D. Kaye, Bennett M. Ford, Brennan M. Abbott, Kalob M. Broocks, Sofia Novacic, Sahar Shekoohi

    Tavapadon, a novel oral dopamine-D1R/D5R partial agonist, has been studied in recent years for the treatment of late-stage development Parkinson’s disease (PD). Levodopa, a dopamine precursor that currently remains the gold-standard first-line therapy for PD motor symptoms, serves as a benchmark against emerging dopaminergic agents. By selectively activating D1-family receptors on direct-pathway medium neurons, Tavapadon differs in that it delivers levodopa-level motor benefit while avoiding its many D2R/D3R-mediated adverse effects. In placebo-controlled trials, Tavapadon produced clear, clinically meaningful gains in motor function and day-to-day activities, as captured by the Unified Parkinson’s Disease Rating Scale (UPDRS). Recent late-stage results have revealed that Tavapadon maintains superior UPDRS outcomes in de novo patients and, when added to levodopa, extended “ON” time periods of reliable motor control free of troublesome dyskinesia, without introducing new safety concerns. In studies, nausea, headache, and somnolence were the most frequent adverse events. Hallucinations, orthostatic hypotension, and impulse-control disorders remained comparable to placebo, reflecting minimal D2R/D3R-mediated effects. Preclinical primate studies have demonstrated levodopa-like motor rescue with markedly less dyskinesia, a pattern mirrored in clinical add-on trials. Collectively, evidence indicates that Tavapadon can match levodopa-mediated symptomatic efficacy, lower dyskinesia liability compared with levodopa or earlier full D1 receptor (D1R) agonists, and offer the convenience of once-daily dosing characteristics, which may bridge the therapeutic gap between levodopa and the current D2R/D3R agonists in PD management. In the present investigation, the emerging clinical role for Tavapadon is described, along with the mechanism of action, clinical efficacy, safety, and future directions.


  • Open Access

    Superficial Cervical Plexus Block for Postoperative Pain Management in Occipital Craniotomies: A Narrative Review

    by Shahab Ahmadzadeh, Bennett M. Ford, Alex V. Hollander, Mary Kathleen Luetkemeier, Tomasina Q. Parker-Actlis, Sahar Shekoohi

    Post-craniotomy pain is common yet often sub-optimally managed because systemic opioids can obscure postoperative neurologic examinations. The superficial cervical plexus block (SCPB) has, therefore, emerged as a targeted regional anesthesia option for occipital craniotomies. The SCPB targets the C2–C4 nerves to anesthetize the occipital scalp region, covering the lesser occipital nerve territory that lies within typical posterior scalp incisions. Clinical evidence shows the block is effective in reducing acute postoperative pain after occipital craniotomy and diminishes opioid requirements. Studies have demonstrated successful and long-lasting analgesia, reductions in 24-h opioid consumption, and a lower incidence of severe pain. Moreover, the technique exhibits a low complication rate and is safer than a deep cervical plexus block because the injection remains superficial and avoids critical vascular and neural structures. When delivered under ultrasound guidance, major adverse events are exceedingly rare. By reducing opioid use, the SCPB can help reduce postoperative complications, allowing earlier neurological assessments and fewer opioid-related side effects. Incorporation of the SCPB into multimodal analgesia regimens can, therefore, accelerate postoperative recovery by providing regionally focused, opioid-sparing pain control without clinically significant sedation. Overall, current data support the SCPB as a dependable, well-tolerated, and clinically practical approach for managing post-craniotomy pain in patients undergoing occipital approaches. In this narrative review, we will discuss the mechanism of action and anatomy, the clinical application, safety and tolerability, patient outcomes, and emerging future directions of the superficial cervical plexus block and how it mitigates post-occipital craniotomy pain.